Addressing an Unmet Need in Dermatomyositis

Dermatomyositis is a chronic autoimmune disorder characterized by immune-mediated inflammation affecting both skeletal muscle and skin. Patients often experience progressive muscle weakness, debilitating fatigue, and distinctive skin manifestations that can be painful or intensely pruritic. These symptoms frequently interfere with daily activities and quality of life, necessitating prolonged treatment.

For decades, disease management has centered on corticosteroids, intravenous immunoglobulin (IVIG), and non-specific immunomodulatory agents. While these therapies can help control symptoms, they are often associated with long-term safety concerns and do not directly target the biological pathways driving the disease.

First-in-Class Oral JAK/TYK2 Inhibitor

Lisraya is a once-daily oral inhibitor of TYK2 and JAK1, enzymes that are part of the Janus kinase (JAK) signaling pathway. Originally discovered by Pfizer and later advanced by Priovant Therapeutics, the therapy is designed to interrupt inflammatory signaling involved in the pathogenesis of dermatomyositis.

By selectively targeting these pathways, brepocitinib aims to reduce the abnormal immune activity responsible for muscle and skin inflammation. The approval introduces a more precise treatment approach compared with traditional broad-spectrum immune suppression.

Commenting on the approval, Dr. Ruth Ann Vleugels of Mass General Brigham and Harvard Medical School described the decision as a major shift in the treatment landscape. She noted that clinicians now have access to a targeted oral therapy capable of improving disease activity across multiple domains while potentially reducing dependence on systemic corticosteroids.

Phase 3 VALOR Trial Supports Approval

The FDA’s decision was based on findings from the Phase 3 VALOR study, a randomized, double-blind, placebo-controlled trial that enrolled 241 adults with dermatomyositis and followed them for 52 weeks.

Patients receiving brepocitinib 30 mg demonstrated superior outcomes compared with placebo when assessed using the Myositis Total Improvement Score (TIS), a validated composite measure evaluating muscle strength, physical function, skin disease activity, laboratory markers, and physician- and patient-reported assessments.

One of the study’s most notable findings was the therapy’s ability to improve disease control while reducing reliance on corticosteroids. By week 52:

• 55% of patients treated with brepocitinib achieved at least moderate improvement on the TIS while maintaining minimal or no steroid use.
• 30% of patients in the placebo group met the same endpoint.

Steroid-sparing benefits were also evident among participants who began the trial on higher corticosteroid doses:

• 62% of patients receiving brepocitinib reduced oral steroid use to 2.5 mg per day or less, compared with 38% of placebo-treated patients.
• 45% of treated patients were able to discontinue corticosteroids completely, versus 29% in the placebo arm.

These findings highlight the potential for brepocitinib not only to improve clinical outcomes but also to lessen exposure to long-term steroid therapy, which can be associated with significant adverse effects.

Broader Development Plans

Roivant leadership emphasized that the approval may be only the first step for brepocitinib. CEO Matt Gline stated that the company believes the therapy could have broader applications across multiple immune-mediated diseases. Ongoing late-stage development programs are evaluating the drug in conditions including non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris, areas where treatment options remain limited.

Outlook

The approval of Lisraya establishes a new treatment category in dermatomyositis and offers patients access to the first targeted oral medicine specifically approved for the condition. Beyond demonstrating meaningful improvements in muscle and skin disease activity, the therapy’s steroid-sparing potential may help address one of the major challenges in long-term disease management. For clinicians and patients alike, the decision signals a new era of precision therapy in a disease that has seen relatively few targeted treatment advances.